MUC1 Expression in Colorectal Cancer is Associated with Malignant Clinicopathological Factors
暂无分享,去创建一个
Koji Nogaki | T. Morohoshi | N. Ohike | T. Kunimura | Y. Takano | K. Kumagai | T. Hobo
[1] Takeshi Suzuki,et al. Application of Autofluorescence Endoscopy for Colorectal Cancer Screening: Rationale and an Update , 2011, Gastroenterology research and practice.
[2] Mei Xu,et al. CDX2 as a marker for intestinal differentiation: Its utility and limitations. , 2011, World journal of gastrointestinal surgery.
[3] E. Oki,et al. A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as first-line treatment for advanced colorectal cancer: A Japanese experience , 2011, Surgery Today.
[4] H. Nagawa,et al. [FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer]. , 2011, Gan to kagaku ryoho. Cancer & chemotherapy.
[5] X. Puig,et al. Clinicopathological and molecular characterization of colorectal micropapillary carcinoma , 2011, Modern Pathology.
[6] Xiong-zeng Zhu,et al. [Expression of mucin glycoproteins and cytokeratins in intrahepatic cholangiocarcinoma]. , 2008, Zhonghua bing li xue za zhi = Chinese journal of pathology.
[7] T. Yeh,et al. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges? , 2008, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.
[8] M. Oka,et al. Adoptive immunotherapy for pancreatic cancer: cytotoxic T lymphocytes stimulated by the MUC1-expressing human pancreatic cancer cell line YPK-1. , 2008, Oncology reports.
[9] J. Gama-Rodrigues,et al. Mucinous colorectal adenocarcinoma: influence of mucin expression (Muc1, 2 and 5) on clinico-pathological features and prognosis , 2008, International Journal of Colorectal Disease.
[10] K. Chayama,et al. Immunohistochemical molecular markers as predictors of curability of endoscopically resected submucosal colorectal cancer. , 2007, World journal of gastroenterology.
[11] J. Scholefield,et al. The role of MUC1 and MUC3 in the biology and prognosis of colorectal cancer , 2007, World journal of surgical oncology.
[12] I. Kazantseva,et al. [Expression of type 1 and type 2 mucins in colonic epithelial tumors]. , 2007, Arkhiv patologii.
[13] Jinn Shiun Chen,et al. Inverse Effects of Mucin on Survival of Matched Hereditary Nonpolyposis Colorectal Cancer and Sporadic Colorectal Cancer Patients , 2006, Clinical Cancer Research.
[14] A. Hölscher,et al. MUC1 and Nuclear β-Catenin Are Coexpressed at the Invasion Front of Colorectal Carcinomas and Are Both Correlated with Tumor Prognosis , 2004, Clinical Cancer Research.
[15] Xiao-qun Zhu,et al. [Expression of mucin MUC1 and MUC2 in colorectal carcinoma and their clinical significance]. , 2002, Ai zheng = Aizheng = Chinese journal of cancer.
[16] A. Hölscher,et al. Comparative evaluation of the prognostic value of MUC1, MUC2, sialyl‐Lewisa and sialyl‐Lewisx antigens in colorectal adenocarcinoma , 2002, Histopathology.
[17] S. Chae,et al. Coexpression of MUC1 with p53 or MUC2 correlates with lymph node metastasis in colorectal carcinomas. , 2002, Journal of Korean medical science.
[18] N. Kohno,et al. Immunoreactive MUC1 Expression at the Deepest Invasive Portion Correlates with Prognosis of Colorectal Cancer , 1998, Oncology.
[19] D. Ota,et al. MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. , 1994, Gastroenterology.